文献速递免疫规划传染病防控与疫情报告

土拉热疫苗:新型Francisella tularensis活疫苗株批次接种后的安全性、反应原性、「Take」皮肤反应及抗体应答——一项2期随机临床试验

Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.
PubMed 文献 · Vaccine · 2017-07-24

这项2期随机临床试验将新生产的土拉热活疫苗株DVC-LVS与已使用数十年的USAMRIID-LVS进行比较,通过划痕法接种228名参与者。两种疫苗在6个月随访中安全性及反应原性均可接受,无严重或3-4级实验室不良事件;第28或56天血清转化率均为94%(p=1.00),但DVC-LVS在第14天血清转化率更高(82% vs 55%,p<0.0001)。作者结论认为DVC-LVS与旧疫苗安全性、反应原性、Take反应及抗体应答相似,且在早期抗体产生方面更优。

要点

  • 两种疫苗接种后6个月内安全性及反应原性均可接受,无严重或3-4级实验室不良事件。
  • DVC-LVS组疫苗Take皮肤反应频率为73%(95%CI 64,81),USAMRIID-LVS组为80%(95%CI 71,87)。
  • 第28或56天血清转化率两组均为94%(p=1.00);第14天DVC-LVS组82% vs USAMRIID-LVS组55%(p<0.0001)。

核心结论

  • DVC-LVS疫苗与旧USAMRIID-LVS疫苗相比具有相似的安全性、反应原性、Take反应及抗体应答,且在早期(第14天)抗体产生方面更优。
  • 在由五个研究诊所人员实施评估的多中心研究中,疫苗接种Take反应并非血清转化的敏感替代指标。

研究设计与样本

  • 2期随机临床试验,比较新批次DVC-LVS与现有USAMRIID-LVS疫苗,通过划痕法接种228名参与者。
  • 在第0、1、2、8、14、28、56和180天评估安全性、反应原性、Take和/或抗体水平。

主要发现

  • 两种疫苗在6个月随访期间均安全,反应原性特征可接受;无严重或3级和4级实验室不良事件。
  • 约23%的参与者报告中度全身性反应原性(主要为头痛或疲倦感),接种两种疫苗者均如此。
  • 接种部位反应原性主要为轻度瘙痒和疼痛。
  • 疫苗Take皮肤反应频率:DVC-LVS组73%(95%CI 64,81),USAMRIID-LVS组80%(95%CI 71,87);比例差的90%CI为-6.9%(-16.4, 2.6)。
  • 第28或56天微量凝集试验血清转化率:DVC-LVS组94%(95%CI 88,98;n=98/104),USAMRIID-LVS组94%(95%CI 87,97;n=103/110)(p=1.00);第14天血清显示DVC-LVS组血清转化更迅速:82%(95%CI 73,89)vs 55%(95%CI 45,65)(p<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tularemia is caused by Francisella tularensis, a gram-negative bacterium that has been weaponized as an aerosol. For protection of personnel conducting biodefense research, the United States Army required clinical evaluation of a new lot of tularemia live vaccine strain manufactured in accordance with Current Good Manufacturing Practices. METHODS: A phase 2 randomized clinical trial compared the new lot (DVC-LVS) to the existing vaccine that has been in use for decades (USAMRIID-LVS). The vaccines were delivered by scarification to 228 participants. Safety, reactogenicity, take and/or antibody levels were assessed on days 0, 1, 2, 8, 14, 28, 56, and 180. PRINCIPAL RESULTS: Both vaccines were safe and had acceptable reactogenicity profiles during six months of follow-up. There were no serious or grade 3 and 4 laboratory adverse events. Moderate systemic reactogenicity (mostly headache or feeling tired) was reported by ∼23% of participants receiving either vaccine. Injection site reactogenicity was mostly mild itchiness and pain. The frequencies of vaccine take skin reactions were 73% (95% CI, 64, 81) for DVC-LVS and 80% (95% CI, 71, 87) for USAMRIID-LVS. The 90% CI for the difference in proportions was -6.9% (-16.4, 2.6). The rates of seroconversion measured by microagglutination assay on days 28 or 56 were 94% (95% CI, 88, 98; n=98/104) for DVC-LVS and 94% (95% CI, 87, 97; n=103/110) for USAMRIID-LVS (p=1.00). Day 14 sera revealed more rapid seroconversion for DVC-LVS relative to USAMRIID-LVS: 82% (95% CI, 73, 89) versus 55% (95% CI, 45, 65), respectively (p<0.0001). MAJOR CONCLUSIONS: The DVC-LVS vaccine had similar safety, reactogenicity, take and antibody responses compared to the older USAMRIID vaccine, and was superior for early (day 14) antibody production. Vaccination take was not a sensitive surrogate for seroconversion in a multi-center study where personnel at five research clinics performed assessments. ClinicalTrials.gov identifier NCT01150695.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mulligan MJ, Stapleton JT, Keitel WA, et al. Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. Vaccine. 2017. PMID: 28750854. doi:10.1016/j.vaccine.2017.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。